Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.48 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.48 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.48 |
| ▸ | THRA | P10827 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19933380 | 0.92 | EGLN1 (0.49) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL19933478 | 0.87 | EGLN1 (0.44) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL19933510 | 0.85 | EGLN1 (0.43) | EGLN1FTOBBOX1EGLN2KDM5B | |
| SCHEMBL19933526 | 0.82 | EGLN1 (0.41) | EGLN1FTOBBOX1EGLN2KDM5B | |
| SCHEMBL19933457 | 0.79 | EGLN1 (0.37) | EGLN1FTOBBOX1 | |
| SCHEMBL19933410 | 0.79 | — | — | |
| SCHEMBL19933384 | 0.76 | EGLN1 (0.57) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL19933463 | 0.75 | EGLN1 (0.62) | EGLN1FTOBBOX1EGLN3 | |
| SCHEMBL19933445 | 0.75 | EGLN1 (0.59) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL19933385 | 0.71 | EGLN1 (0.58) | EGLN1FTOBBOX1KDM5BKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180065933-A1 | DEUTERIUM-ENRICHED HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE ENZYME INHIBITORS | AKEBIA THERAPEUTICS, INC. (US) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065933-A1 | DEUTERIUM-ENRICHED HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE ENZYME INHIBITORS | HIF1AN, EGLN3, EGLN2 | EGLN1 6/4885FTO 971/4885BBOX1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.